newsfilter
← Latest News
GlobeNewswire·

Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress

Continued clinical progress for the vebreltinib registration-enabling program, including new data in non-CNS MET fusion tumors and non-small cell lung cancer (NSCLC) with MET amplification $25.9 million in cash and cash